Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,441,958

« Back to Dashboard

Summary for Patent: 5,441,958

Title: Ophthalmic compositions comprising emedastine and methods for their use
Abstract:Topical ophthalmic compositions comprising 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)-benzimidazole and its ophthalmically acceptable acid addition salts have been found to be useful in treating allergic conjunctivitis and related ailments.
Inventor(s): Yanni; John M. (Burleson, TX), Robertson; Stella M. (Arlington, TX), Okumura; Shigetoshi (Nara, JP), Tanaka; Hitoshi (Nara, JP), Saito; Tadayuki (Osaka, JP)
Assignee: Alcon Laboratories, Inc. (Fort Worth, TX)
Application Number:08/163,973
Patent Claim Types:
see list of patent claims
Use;
Patent PDF download available with subscription

No matches for this query

Foreign Priority and PCT Information for Patent: 5,441,958

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan4-329216Dec 09, 1992

International Patent Family for Patent: 5,441,958

Country Document Number Publication Date Supplementary Protection Certificate SPC Country SPC Expiration
Spain2137352Dec 16, 1999
Australia667613Mar 28, 1996
Austria185696Nov 15, 1999
European Patent Office0673250Oct 20, 1999
World Intellectual Property Organization (WIPO)9413299Jun 23, 1994
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc